Company news: Gilead and Janssen

Share this article:

Gilead filed NDAs for two new HIV-infection fighters, the integrase inhibitor elvitegravir and the “boosting” agent cobicistat. Both drugs are also components of the Quad once-daily single tablet HIV regimen, currently under review by US and European authorities. The filings follow Gilead agreements with Bristol-Myers Squibb and Janssen to develop fixed-dose combinations of cobicistat with darunavir and atazanavir, respectively. The Quad contains four Gilead compounds: elvitegravir, cobicistat and Truvada, which itself is a combination of Gilead's emtricitabine and tenofovir disoproxil fumarate.

Janssen submitted an NDA for bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults. The firm is seeking accelerated approval. Bedaquiline would be the first drug with a new mechanism of action for TB in more than 40 years and the first and only one specifically indicated for MDR-TB.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.